Anhco Nguyen Sells 1,664 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 1,664 shares of Atara Biotherapeutics stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $11.20, for a total transaction of $18,636.80. Following the transaction, the chief executive officer now directly owns 77,454 shares of the company’s stock, valued at approximately $867,484.80. This trade represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Atara Biotherapeutics Trading Up 8.1 %

NASDAQ:ATRA opened at $11.47 on Friday. The stock has a 50 day moving average of $9.19 and a two-hundred day moving average of $10.11. Atara Biotherapeutics, Inc. has a 12 month low of $6.50 and a 12 month high of $39.50. The firm has a market cap of $66.07 million, a P/E ratio of -0.44 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the firm posted ($16.50) earnings per share. On average, research analysts forecast that Atara Biotherapeutics, Inc. will post -12.12 earnings per share for the current year.

Wall Street Analyst Weigh In

ATRA has been the subject of a number of recent analyst reports. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price objective for the company from $25.00 to $18.00 in a report on Friday, August 16th. Canaccord Genuity Group lifted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $16.67.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of large investors have recently made changes to their positions in the stock. Delap Wealth Advisory LLC purchased a new stake in Atara Biotherapeutics in the 1st quarter valued at $29,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Atara Biotherapeutics in the second quarter valued at about $53,000. Cubist Systematic Strategies LLC acquired a new stake in Atara Biotherapeutics during the second quarter worth about $79,000. State Street Corp raised its stake in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the period. Finally, FMR LLC grew its stake in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares during the period. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.